|
|
Volumn 20, Issue 3, 2002, Pages 339-342
|
|
Phase II trial of pyrazoloacridine in advanced non-small cell carcinoma of the lung - A Kansas Cancer Institute and Thompson Cancer Survival Center Study
a
b
a
a
a
c
|
|
Author keywords
Lung neoplasms; Pyrazoloacridine
|
|
Indexed keywords
2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE;
DNA;
RNA;
ACRIDINE DERIVATIVE;
ANTINEOPLASTIC AGENT;
PYRAZOLE DERIVATIVE;
ADULT;
AGED;
ANEMIA;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
CANCER SURVIVAL;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CYTOTOXICITY;
EMBOLISM;
ESOPHAGITIS;
FATIGUE;
FEMALE;
GRANULOCYTOPENIA;
HEART DISEASE;
HUMAN;
HYPERBILIRUBINEMIA;
INFECTION;
LUNG CARCINOMA;
LUNG NON SMALL CELL CANCER;
MALE;
NAUSEA AND VOMITING;
NEUROTOXICITY;
PHASE 2 CLINICAL TRIAL;
PHLEBITIS;
PRIORITY JOURNAL;
SKIN DISCOLORATION;
THROMBOCYTOPENIA;
THROMBOPHLEBITIS;
DOSE RESPONSE;
LUNG TUMOR;
MIDDLE AGED;
PATHOLOGY;
SURVIVAL;
ACRIDINES;
AGED;
AGED, 80 AND OVER;
ANTINEOPLASTIC AGENTS;
CARCINOMA, NON-SMALL-CELL LUNG;
DOSE-RESPONSE RELATIONSHIP, DRUG;
FEMALE;
HUMAN;
LUNG NEOPLASMS;
MALE;
MIDDLE AGE;
PYRAZOLES;
SURVIVAL ANALYSIS;
HUMANS;
MIDDLE AGED;
|
|
EID: 0036021253
PISSN: 01676997
EISSN: None
Source Type: Journal
DOI: 10.1023/A:1016293527755 Document Type: Article |
|
Times cited : (11)
|
|
References (13)
|
